Searchable abstracts of presentations at key conferences in endocrinology

ea0011p608 | Neuroendocrinology and behaviour | ECE2006

Bone mass and metabolism in active acromegaly – no impact of gonadal status. a study of 73 patients

Fougner SL , Godang K , Ueland T , Schreiner T , Bollerslev J

Background: Growth hormone (GH) is known to have stimulatory effects on bone tissue through a complex interaction of GH, IGF-1 and IGFBPs. The gonadal status is also thought to influence bone metabolism. Bone mass in patients with acromegaly reflects the long-time effects of GH excess on bone. However, data on bone status in acromegaly have been conflicting.Objective: The object of the study was to examine the impact of chronic GH excess on bone mass and...

ea0011p514 | Endocrine tumours and neoplasia | ECE2006

Surgical cure with preserved pituitary function is rare in acromegalic patients. Results from the Preoperative Octreotide Treatment of Acromegaly (POTA) study

Carlsen SM , Schreiner T , Anderud S , Johannesen Ø , Svartberg J , Bollerslev J

Background: In many acromegalics neurosurgery is unable to control GH secretion while it may harm the normal pituitary.Objective: To investigate the effect of pre-treatment with octreotide on surgical outcome in acromegaly.Methods: Previously untreated acromegalics were randomised directly to surgery or octreotide for six month before transsphenoidal surgery. Three months postoperatively patients underwent OGTT and Insulin Toleranc...

ea0064011 | Effect of exogenous testosterone administration on serum oestradiol levels in assigned female at birth transgender people: result from a large transgender cohort | BES2019

Effect of exogenous testosterone administration on serum oestradiol levels in assigned female at birth transgender people: result from a large transgender cohort.

Defreyne J , Aers XP , Collet S , Wiepjes CM , Fisher AD , Schreiner T , Den Heijer M , Kaufman JM , T'Sjoen G

Aim: The changes in serum oestradiol levels in assigned female at birth (AFAB) transgender people receiving testosterone therapy have not been elucidated. How serum oestradiol levels change after initiation of testosterone therapy, if these levels should be monitored and whether altered oestradiol levels will result in adverse health outcomes, remains unclear.Methods: This prospective cohort study was part of the European Network for the Investigation of...

ea0029oc1.6 | Pituitary Clinical I | ICEECE2012

Normal weight adult patients with Prader–Willi syndrome are not protected from insulin resistance during treatment with GH: results from a 12 month prospective study

Jorgensen A. , Ueland T. , Sode-Carlsen R. , Schreiner T. , Rabben K. , Farholt S. , Hoybye C. , Christiansen J. , Bollerslev J.

Background: Diabetes mellitus is prevalent in adults with Prader–Willi syndrome (PWS), and GH therapy may deteriorate glucose balance.Design: We prospectively investigated effects of 12 months of GH treatment on body composition and insulin resistance in relation to BMI in forty-two adults, mean(±S.D.) age 28.5±6.7 years with genetically verified PWS. Three patients with known diabetes were excluded. Data from baseline and 1...

ea0071010 | Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: A prospective cohort study (ENIGI) | BES2020

Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: A prospective cohort study (ENIGI)

J Defreyne , Y Vanwonterghem , S Collet , S Iwamoto , CM Wiepjes , AD Fisher , T Schreiner , M Den Heijer , G T'Sjoen

Background: Previous cross-sectional studies have described amenorrhea in cohorts of transgender men on intramuscular or subcutaneous testosterone injections. It remains uncertain which testosterone preparations most effectively suppress vaginal bleeding and when amenorrhea occurs after testosterone initiation.Aim: To investigate the clinical effects of various testosterone preparations on vaginal bleeding and spotting in transgender men.<p class="ab...